Trial · NCT04273932
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Plasma alpha-synuclein assessed by ultra-sensitive, immunomagnetic reduction assay (MagQu, LLC, Surprise, AZ). | Change from baseline to 24 weeks | |
| Primary | Peripheral blood mononuclear cell (PBMC) Nurr1 mRNA levels by real-time polymerase chain reaction. | Change from baseline to 24 weeks | |
| Primary | PBMC phosphorylated (p) and total (t) levels of pSerine9 and t-glycogen synthase kinase-3B | Change from baseline to 24 weeks | |
| Primary | Plasma brain-derived neurotrophic factor (BDNF). | Change from baseline to 24 weeks | |
| Primary | PBMC pThreonine308 and t-protein kinase B (Akt). | Change from baseline to 24 weeks | |
| Secondary | Trough, steady-state plasma lithium levels by ICP/MS | Change from baseline to 24 weeks | |
| Secondary | Patient tolerability | Up to 24 weeks | Assessed by patient reported adverse events. |
| Secondary | Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS), Part III (Motor Examination) and question 1.11 (Constipation Problems) in the "on" state | Change from baseline to weeks 12 and 24. | Score range 0-132 with higher values indicating more severe symptoms. |
| Secondary | Parkinson's Anxiety Scale | Change from baseline to weeks 12 and 24. | Score range 0-48 with higher values indicating more severe symptoms. |
| Secondary | Geriatric Depression Scale-15 | Change from baseline to weeks 12 and 24. | Score range 0-15 with higher values indicating more severe symptoms. |
| Secondary | Fatigue Severity Scale | Change from baseline to weeks 12 and 24. | Score range 9-56 with higher values indicating more severe symptoms. |
| Secondary | Insomnia Severity Index | Change from baseline to weeks 12 and 24. | Score range 0-28 with higher values indicating more severe symptoms. |
| Secondary | Parkinson's Disease Questionnaire-8 | Change from baseline to weeks 12 and 24. | Score range 0-32 with higher values indicating more severe symptoms. |
| Secondary | Montreal Cognitive Assessment (MoCA) | Change from screening to week 24 | Score range 0-30 with higher values indicating more severe symptoms. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04273932/registered